- Home
- SPHR vs ETNB Comparison
SPHR vs ETNB Comparison
Compare SPHR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- ETNB
- Stock Information
- Founded
- SPHR 2020
- ETNB 2018
- Country
- SPHR United States
- ETNB United States
- Employees
- SPHR N/A
- ETNB 93
- Industry
- SPHR Services-Misc. Amusement & Recreation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SPHR Consumer Discretionary
- ETNB Health Care
- Exchange
- SPHR Nasdaq
- ETNB Nasdaq
- Market Cap
- SPHR 2.1B
- ETNB 2.2B
- IPO Year
- SPHR N/A
- ETNB 2019
- Fundamental
- Price
- SPHR $59.85
- ETNB $14.83
- Analyst Decision
- SPHR Buy
- ETNB Buy
- Analyst Count
- SPHR 8
- ETNB 10
- Target Price
- SPHR $53.25
- ETNB $22.31
- AVG Volume (30 Days)
- SPHR 1.3M
- ETNB 9.5M
- Earning Date
- SPHR 11-11-2025
- ETNB 11-06-2025
- Dividend Yield
- SPHR N/A
- ETNB N/A
- EPS Growth
- SPHR N/A
- ETNB N/A
- EPS
- SPHR N/A
- ETNB N/A
- Revenue
- SPHR $1,040,932,000.00
- ETNB N/A
- Revenue This Year
- SPHR $9.94
- ETNB N/A
- Revenue Next Year
- SPHR $9.84
- ETNB N/A
- P/E Ratio
- SPHR N/A
- ETNB N/A
- Revenue Growth
- SPHR 1.37
- ETNB N/A
- 52 Week Low
- SPHR $23.89
- ETNB $4.16
- 52 Week High
- SPHR $68.00
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- SPHR 57.77
- ETNB 79.17
- Support Level
- SPHR $62.14
- ETNB $14.67
- Resistance Level
- SPHR $68.00
- ETNB $14.93
- Average True Range (ATR)
- SPHR 3.01
- ETNB 0.09
- MACD
- SPHR -0.24
- ETNB 0.06
- Stochastic Oscillator
- SPHR 28.69
- ETNB 41.03
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).